sub:assertion {
  d:DB06695 dv:ddi-interactor-in dr:DB06695_DB08827 .
  d:DB08827 dv:ddi-interactor-in dr:DB06695_DB08827 .
  dr:DB06695_DB08827 dct:identifier "drugbank_resource:DB06695_DB08827" ;
    dct:title "DDI between Dabigatran etexilate and Lomitapide - Dabigatran is a p-glycoprotien (P-gp) substrate. Levels of dabigatran may increase if coadministered with lomipatide, which is a P-gp inhibitor. Thus, it is recommended to dose reduce P-gp substrates (such as ambrisentan, aliskiren, colchicine, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) with the concomitant use of lomipatide."@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label "DDI between Dabigatran etexilate and Lomitapide - Dabigatran is a p-glycoprotien (P-gp) substrate. Levels of dabigatran may increase if coadministered with lomipatide, which is a P-gp inhibitor. Thus, it is recommended to dose reduce P-gp substrates (such as ambrisentan, aliskiren, colchicine, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) with the concomitant use of lomipatide.   [drugbank_resource:DB06695_DB08827]"@en .
}